newsfilter
← Latest News
Business Wire·

Janux Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights

Enrollment ongoing for PSMA-TRACTr (JANX007) in prostate cancer and EGFR-TRACTr (JANX008) in solid tumors Update on JANX007 data and doses selected for expansion cohorts is anticipated in 2H 2024 Appointed Eric